Sales and Marketing

News

Novo Nordisk returns to ABPI fold after two-year suspension

Novo Nordisk has reached the end of its two-year suspension from the ABPI for breaches of its code of practice after making "sustained improvements."

News

Novo Nordisk follows Lilly into DTC obesity drug market

Novo Nordisk has launched direct-to-consumer sales of its obesity drug Wegovy for uninsured or under-insured people at $499 per month.

News

Lilly launches discounted high-strength Zepbound vials in US

Eli Lilly's drive to provide as many treatment options as possible for its obesity drug Zepbound has continued with the launch of new high-dose vials.

News

Pfizer drops Beqvez, leaving its gene therapy cupboard bare

Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable.

News

BMS extends its cost-cutting drive by another $2bn

BMS is extending its bid to cut costs by $1.5bn before the end of this year, backed by 2200 job cuts, adding a target of another $2bn by end-2027.

News

Pressure relieved on AZ as details of Chinese probe emerge

AstraZeneca's exposure to liability in a Chinese investigation into illegal drug imports appears to be much less than had been feared.

Novo Nordisk returns to ABPI fold after two-year suspension

Novo Nordisk follows Lilly into DTC obesity drug market

Lilly launches discounted high-strength Zepbound vials in US

Pfizer drops Beqvez, leaving its gene therapy cupboard bare

BMS extends its cost-cutting drive by another $2bn

Pressure relieved on AZ as details of Chinese probe emerge

DNA testing can help right racial imbalance in breast cancer

Using AI-driven synthetic personas to take your insights fur...

Sales and Marketing

Editor's Picks